Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males

Completed · Not applicable · Has a placebo group

Conditions studied: Metabolic Syndrome, Obesity

In brief

Eight weeks supplementation of alpha lipoic acid (known superantioxidant already produced by the body) will significantly improve metabolic syndrome markers (e.g., excess body weight, blood pressure, glucose, insulin, blood lipids, and self-report measures) in young (18-25 years) overweight or obese males compared to placebo (cellulose starch). If the hypothesis is supported, alpha lipoic acid ingestion could be beneficial in reducing disease risk and enhancing metabolic dysfunction in ethnic individuals. Therefore, the purpose is to establish the impact alpha lipoic acid has on the modifiable markers associated with metabolic perturbations consistent with metabolic syndrome in males.

Key facts

Study ID

NCT03342599

Run by

University of La Verne

People needed

16

Starts

2013-10-01

Expected to finish

2016-09-01

Last updated by the study team

2017-11-17

Who can join

Age: 18 and older, up to 35. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Overweight or obese (body mass index 25 - 35 kg/m2)
• Males (18-35 years)
• Able to ingest supplement or placebo

You may not qualify if…

• Female (due to menstrual cycle fluctuations)
• Unable to read English at the time of consent
• Have a body mass index under 25 kg/m2 or over 35 kg/m2
• Diabetes
• Impaired glucose tolerance (fasting plasma glucose levels >110 mg/dL
• Hypertension (SBP>130mmHg or DBP>90mmHg)
• Cardiovascular problems or disease
• Psychiatric problems
• History of alcohol abuse (intake of >500 g/wk in the last year)
• Current or recent (in the past 3 years) smoking
• Certain medication or dietary supplement use (medications or dietary supplements known to cause weight loss/gain or metabolic improvements/dysfunction. Paxil or (paroxetine), Prozac (fluoxetine), Remeron (mirtazapine), Zyprexa (olanzapine), Deltasone (prednisone), Thorazine (chlorpromazine), Elavil, Endep, Vanatrip (amitriptyline), Depakote (valproic acid), Allegra (fexofenadine and pseudoephedrine), Diabinese or Insulase
• Symptoms of chronic or current infection
• A chronic inflammatory condition
• Any thyroid condition, and/or liver disease or malignancy

Where it is running

• University of La Verne Kinesiology Laboratory — La Verne, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.